Curis, Inc.

( )
CRIS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -6.60%123.470.0%$1121.14m
OCGNOcugen, Inc. -1.26%8.630.0%$797.67m
AMGNAmgen, Inc. 0.04%227.811.3%$546.41m
REGNRegeneron Pharmaceuticals, Inc. 0.35%463.192.7%$534.62m
NVAXNovavax, Inc. -9.71%157.8792.9%$533.68m
GILDGilead Sciences, Inc. 0.20%64.751.0%$502.19m
ILMNIllumina, Inc. -3.82%383.623.5%$481.24m
VRTXVertex Pharmaceuticals, Inc. 0.76%213.581.9%$461.68m
ALXNAlexion Pharmaceuticals, Inc. -0.03%150.062.0%$329.21m
BNGOBioNano Genomics, Inc. 8.67%7.770.0%$322.31m
CRSPCRISPR Therapeutics AG -0.90%113.620.6%$321.43m
BIIBBiogen, Inc. -0.26%270.011.7%$296.77m
EXASEXACT Sciences Corp. -4.17%116.5718.4%$244.18m
SGENSeagen Inc. -0.45%148.685.8%$208.59m
PACBPacific Biosciences of California, Inc. -6.49%27.377.2%$176.05m

Company Profile

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.